University Hospital La Timone world’s first to treat patients with Leksell Gamma Knife Icon, Elekta’s latest generation cranial radiosurgery system
MARSEILLES, France, August 26, 2015 – On August 10, doctors at University Hospital La Timone (Marseilles, France) used their new Leksell Gamma Knife® Icon™ system to treat a metastasis in the brain of a 71-year-old female patient. This single-session treatment was the first time La Timone physicians had harnessed the system’s advanced motion management and imaging capabilities to enable therapy using mask-based head fixation instead of the traditional rigid stereotactic frame. With Icon, La Timone physicians are predicting a significant increase in the volume of patients suitable for frameless Gamma Knife radiosurgery.
In the days following, doctors treated three additional patients with metastases using the same method. Then, on August 17, the hospital achieved another Icon milestone – its first patient to begin frameless, multi-session (hypofractionated) treatment of a benign tumor.
“This 77-year-old female patient had a cavernous sinus meningioma that was too close to the optic nerve and chiasm to treat with a single high dose – it would have been too high of a dose to avoid threatening these sensitive structures,” says Professor Jean Régis, MD, a neurosurgeon and program director for University Hospital La Timone’s Gamma Knife program, which launched traditional frame-based Gamma Knife® radiosurgery treatments with Icon in mid-July. “Therefore, she received a hypofractionated treatment, which divided her therapy into five sessions over five days to decrease the risk of injuring visual pathways.”
Icon features especially important for frameless therapy
When performing frameless Gamma Knife radiosurgery with Icon, it is crucial that patient motion be managed and that the patient’s position can be precisely reproduced in hypofractionated treatments.
Gamma Knife Icon addresses both of these imperatives. Icon provides an integrated cone-beam CT (CBCT) workflow that enables doctors to check the patient’s position against planning images. After a thermoplastic mask is custom-fitted to the patient’s head, an initial CBCT is performed to obtain a reference image, which is then fused with an MRI image to enable the clinician to develop the plan. The patient is then placed on the treatment couch with the mask.
“Because the patient is never precisely in the same position as in these first scans, you acquire a new CBCT scan,” Prof. Régis explains. “In a few seconds, the GammaPlan® software automatically adapts the plan to the new position of the patient’s head and displays the dose distribution before and after this automated recalculation. This allows the physician to identify any discrepancies between the initial plan and the recalculated plan according to the new patient position. It’s important to reiterate that this is a plan correction, not physically correcting the patient’s position. So far, the differences in the plan – before and after adaptation to the patient’s latest position – have been clinically insignificant, so we haven’t rejected any of the adapted plans.”
During treatment, patient motion is managed through the high-definition motion management system, which monitors the patient’s head position via infrared tracking of markers.
“If the patient coughs or moves her head and that motion exceeds a safety threshold, the system automatically stops delivering the radiation,” he observes. “This is critical feature for patient safety in these frameless treatments. The on-the-fly intrafraction, automated adaptation of the planning to patient position is a new and interesting capability of Icon.”
At press time, Hospital La Timone had used Leksell Gamma Knife Icon to treat a total of 33 patients using either frame-based or frameless methods.
To learn more about Leksell Gamma Knife Icon, visit careforthebrain.com.
# # #
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: firstname.lastname@example.org
Time zone: CET: Central European Time
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: email@example.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on August 26, 2015.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.